{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:57:23Z","timestamp":1789480643186,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Biochemistry and Biophysics"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.abb.2017.08.003","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T16:16:33Z","timestamp":1502208993000},"page":"31-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1)"],"prefix":"10.1016","volume":"631","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4491-603X","authenticated-orcid":false,"given":"Alberto","family":"Bresciani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Missineo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Cerretani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fezzardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia","family":"Tomei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Oscar","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Santoprete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8292-6346","authenticated-orcid":false,"given":"Raffaele","family":"Ingenito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pacifici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Munoz-Sanjuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Toledo-Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry C.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abb.2017.08.003_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biocel.2006.07.001","article-title":"Free radicals and antioxidants in normal physiological functions and human disease","volume":"39","author":"Valko","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.abb.2017.08.003_bib2","article-title":"Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases","author":"Gan","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.abb.2017.08.003_bib3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5607\/en.2015.24.4.325","article-title":"The role of oxidative stress in neurodegenerative diseases","volume":"24","author":"Kim","year":"2015","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.abb.2017.08.003_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/1568007033482959","article-title":"Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis","volume":"2","author":"Di Matteo","year":"2003","journal-title":"Curr. Drug Targets. CNS Neurol. Disord."},{"key":"10.1016\/j.abb.2017.08.003_bib5","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/mds.26331","article-title":"Therapeutic advances in Huntington's disease","volume":"30","author":"Shannon","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.abb.2017.08.003_bib6","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.2174\/092986711803414368","article-title":"Antioxidant therapy: current status and future prospects","volume":"18","author":"Firuzi","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.abb.2017.08.003_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.freeradbiomed.2013.04.010","article-title":"Antioxidants as therapies: can we improve on nature?","volume":"66","author":"Murphy","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.abb.2017.08.003_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2217\/nmt.15.19","article-title":"Targeting mitochondrial metal dyshomeostasis for the treatment of neurodegeneration","volume":"5","author":"Liddell","year":"2015","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.abb.2017.08.003_bib9","first-page":"201522872","article-title":"Nrf2 mitigates LRRK2- and \u03b1-synuclein-induced neurodegeneration by modulating proteostasis","author":"Skibinski","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.abb.2017.08.003_bib10","doi-asserted-by":"crossref","first-page":"9926","DOI":"10.1073\/pnas.91.21.9926","article-title":"Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2\/AP1 repeat of the beta-globin locus control region","volume":"91","author":"Moi","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.abb.2017.08.003_bib11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1089\/ars.2012.4944","article-title":"The gasotransmitter hydrogen sulfide induces nrf2-target genes by inactivating the keap1 ubiquitin ligase substrate adaptor through formation of a disulfide bond between cys-226 and cys-613","volume":"19","author":"Hourihan","year":"2013","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.abb.2017.08.003_bib12","doi-asserted-by":"crossref","first-page":"18838","DOI":"10.1073\/pnas.1007387107","article-title":"Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals","volume":"107","author":"McMahon","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.abb.2017.08.003_bib13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1128\/MCB.01080-08","article-title":"The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds","volume":"29","author":"Kobayashi","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.abb.2017.08.003_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1101\/gad.13.1.76","article-title":"Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain","volume":"13","author":"Itoh","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.abb.2017.08.003_bib15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2443.2003.00640.x","article-title":"Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles","volume":"8","author":"Itoh","year":"2003","journal-title":"Genes Cells"},{"key":"10.1016\/j.abb.2017.08.003_bib16","doi-asserted-by":"crossref","first-page":"10941","DOI":"10.1128\/MCB.24.24.10941-10953.2004","article-title":"Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex","volume":"24","author":"Zhang","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.abb.2017.08.003_bib17","doi-asserted-by":"crossref","first-page":"21592","DOI":"10.1074\/jbc.M300931200","article-title":"Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression","volume":"278","author":"McMahon","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.abb.2017.08.003_bib18","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1073\/pnas.94.10.5361","article-title":"Functional antioxidant responsive elements","volume":"94","author":"Wasserman","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.abb.2017.08.003_bib19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/med.21257","article-title":"Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents","volume":"32","author":"Magesh","year":"2012","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.abb.2017.08.003_bib20","first-page":"1292","article-title":"The keap1-nrf2-ARE pathway as a potential preventive and therapeutic target: an update","volume":"29","author":"Lu","year":"2016","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.abb.2017.08.003_bib21","doi-asserted-by":"crossref","first-page":"54750","DOI":"10.1074\/jbc.M410073200","article-title":"Crystal structure of the Kelch domain of human Keap1","volume":"279","author":"Li","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.abb.2017.08.003_bib22","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1016\/j.bmcl.2013.03.013","article-title":"Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction","volume":"23","author":"Hu","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.abb.2017.08.003_bib23","article-title":"Discovery of potent keap1-nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis","author":"Jiang","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.abb.2017.08.003_bib24","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1021\/acsmedchemlett.5b00407","article-title":"Polar recognition group study of keap1-nrf2 protein-protein interaction inhibitors","volume":"7","author":"Lu","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.abb.2017.08.003_bib25","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1021\/acs.jmedchem.6b00228","article-title":"Monoacidic inhibitors of the Kelch-like ECH-associated protein 1: nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein\u2013protein interaction with high cell potency identified by fragment-based discovery","volume":"59","author":"Davies","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.abb.2017.08.003_bib26","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/j.1747-0285.2011.01240.x","article-title":"Kinetic analyses of Keap1-Nrf2 interaction and determination of the minimal Nrf2 peptide sequence required for Keap1 binding using surface plasmon resonance","volume":"78","author":"Chen","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.abb.2017.08.003_bib27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/1087057111430124","article-title":"Optimization of fluorescently labeled Nrf2 peptide probes and the development of a fluorescence polarization assay for the discovery of inhibitors of Keap1-Nrf2 interaction","volume":"17","author":"Inoyama","year":"2012","journal-title":"J.\u00a0Biomol. Screen"},{"key":"10.1016\/j.abb.2017.08.003_bib28","first-page":"42","article-title":"A\u00a0universal homogeneous assay for high-throughput determination of binding kinetics","volume":"468C","author":"Schiele","year":"2014","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.abb.2017.08.003_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"Oldenburg, a simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J.\u00a0Biomol. Screen"},{"key":"10.1016\/j.abb.2017.08.003_bib30","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrd1500","article-title":"Opinion: biochemical mechanisms of drug action: what does it take for success?","volume":"3","author":"Swinney","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.abb.2017.08.003_bib31","first-page":"2887","volume":"vol. 26","author":"Tong","year":"2006"},{"key":"10.1016\/j.abb.2017.08.003_bib32","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1038\/sj.emboj.7601243","article-title":"Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling","volume":"25","author":"Lo","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.abb.2017.08.003_bib33","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/cmdc.201300525","article-title":"Binding mode and structure-activity relationships around direct inhibitors of the Nrf2-Keap1 complex","volume":"9","author":"Jnoff","year":"2014","journal-title":"ChemMedChem"}],"container-title":["Archives of Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003986117303843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003986117303843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T08:57:11Z","timestamp":1574931431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003986117303843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":33,"alternative-id":["S0003986117303843"],"URL":"https:\/\/doi.org\/10.1016\/j.abb.2017.08.003","relation":{},"ISSN":["0003-9861"],"issn-type":[{"value":"0003-9861","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1)","name":"articletitle","label":"Article Title"},{"value":"Archives of Biochemistry and Biophysics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abb.2017.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}